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Systematic Review and Meta-Analysis

OPEN

Cost-effectiveness and diagnostic accuracy of
telemedicine in macular disease and diabetic
retinopathy
A systematic review and meta-analysis
∗

Waqas Ullah, MDa, , Sana Khan Pathan, MDb, Ankur Panchal, MDc, Swapna Anandan, MDb,
Kaiser Saleem, MDb, Yasar Sattar, MDd, Ejaz Ahmad, MDe, Maryam Mukhtar, MDf, Haq Nawaz, MDb
Abstract
Objective: To determine cost-effectiveness and the diagnostic accuracy of teleophthalmology (TO) in the detection of macular
Downloaded from https://journals.lww.com/md-journal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3y7wDLvMZ9kwodZ/WZ/8q6Ye4/OxC4B9SfFMwhHDdbRk= on 08/07/2020

edema (ME) and various grades of diabetic retinopathy (DR).
Methods: MEDLINE, EMBASE, and Cochrane databases were searched for TO, ME, and DR on May 25, 2016. The search was
updated on April 2, 2019. Pooled sensitivity and speciﬁcity for ME and various grades of DR were determined using Meta-Disc
software. A systematic review of the articles discussing the cost-effectiveness of TO screening was also performed.
Results: Thirty-three articles on the diagnostic accuracy and 28 articles on the cost-effectiveness were selected.
Conclusions: Telescreening is moderately sensitive but very speciﬁc for the diagnosis of diabetic retinopathy. Non-mydriatic

Teleretinal screening services are cost-effective, decrease clinics workload, and increase patient compliance if provided free of cost in
remote low socioeconomic regions.
Abbreviations: CSME = clinically signiﬁcant macular edema, DME = diabetic macular edema, DoD = Department of Defense, DR

= diabetic retinopathy, ETDRS = Early Treatment Diabetic Retinopathy Screening, IHS = Indian Health Service, JVN = Joslin Vision
Network, ME = macular edema, NPDR = non-diabetic proliferative diabetic retinopathy, PDR = proliferative diabetic retinopathy,
QALY = quality-adjusted life-year, TO = teleophthalmology, VA = Department of Veterans Affairs.
Keywords: diabetic retinopathy, macular edema, teleophthalmology

Editor: Suleyman Demircan.

1. Introduction

Financial Disclosure: None.

Recent surveys indicate that approximately 382 million of the
world population and 29.1 million of the US population has
diabetes mellitus.[1,2] If no action has been taken, this number will
double by 2035.[1] With such a signiﬁcant portion of the
population affected by diabetes, managing complications of this
disease are paramount. The most common complication of
diabetes is diabetic retinopathy (DR), affecting about 28% of the
diabetic population.[3] According to WHO, DR accounts for
almost 17% of all cases of blindness in the USA and Europe,
and the number of Americans with DR will nearly double from
7.7 million to 14.6 million by the end of 2050.[4] Good glycemic
control, early diagnosis, and prompt management of DR can
delay the progression of DR into blindness.[5] Despite this
knowledge, only about 55% of the diabetic patients in the United
States receive retinopathy screening.[6] Similarly, the systematic
implementation of DR testing is not common in many low and
middle-income countries.[5,7] The main reasons responsible for
the poor compliance to the DR screening are high testing
expenses, inadequate health care facilities, and limited access to
conventional screening strategies.[8] Teleophthalmology recently
has gained particular importance as an alternative screening
method to overcome the barriers in the face of DR screening.[9]
Teleretinal technology is believed to improve access and reduce
the cost of the DR and ME screening. However, the diagnostic
accuracy and cost of this screening modality depend on many
variables including the use of pupillary mydriasis, an instrument
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used, the qualiﬁcations of the photographer, number of
photographic ﬁelds, and the image interpreter. Many studies
have been done to discuss the utility of this technology, but the
literature on the cost-effectiveness and diagnostic accuracy of
Teleretinal screening are yet limited. We present the results of a
systematic review and meta-analysis of studies evaluating the
cost-effectiveness and pooled sensitivity and speciﬁcity of TO in
DR and ME screening.

using the Meta-Disc software, RevMan Version 5.3, London,
United Kingdom.

2. Methods

3. Results

2.1. Search strategy and selection criteria

The combined systematic search strategy identiﬁed a total of
3814 articles. After excluding 1201 duplicate items, the
remaining 2613 pieces of literature were screened for relevance
based on their titles and abstracts, and 2183 articles were further
excluded. A total of 430 were deemed potentially eligible and
retrieved for a full review. After a detailed review, a total of 369
articles were further excluded for the following reasons: screening
strategies other than teleophthalmology (n = 145), telemedicine
services of diabetic care (n = 27), cost of diabetic care (n = 26),
telemedicine for treatment of DR (n = 48), diabetes prevalence
and management (n = 62), telerehabilitation of diabetics (n = 18),
telemedicine on visual acuity and retinitis pigmentosa (n = 9), and
articles on Teleretinal diabetic prevalence (31). Thirty-three
articles on the diagnostic accuracy and 28 articles on the costeffectiveness were included.
Figure 1 presents a Preferred Reporting Item for Systematic
Reviews and Meta-analysis (PRISMA) ﬂowchart of the study
selection process along with reasons for study exclusion.

2.4. Quality assessment
The quality assessment of all the included articles studies was
performed using the RevMan 5.3. Selection, detection, attrition,
and reporting bias for all studies was assessed.

The initial literature search for relevant articles was performed on
May 25, 2016, using MEDLINE (PubMed, Ovid), Embase, and
Cochrane databases. The search was updated on April 2, 2019.
There was no language or time restriction placed on the search.
The search strategies included various combinations of textwords and medical subject headings (MeSH) to generate 2 subsets
of citations: one for ME or DR, using the MeSH and terms like
“macular edema,” “diabetic retinopathy,” “diabetic maculopathy,” “diabetic macular edema,” “diabetic ophthalmopathy,”
“diabetic eye disease,” and “diabetic ocular disease” and the
other for teleophthalmology using terms and MeSH like
“telemedicine,” “telehealth,” “mhealth,” “ehealth,” “medical
informatics,” “clinical decision support system,” “computerassisted decision making,” “information system,” “teleophthalmology diabetes,” “tele maculopathy diabetes,” “tele healthcare,” “mobile health,” “health information technology,”
“software-assisted analysis.” The terms from the 2 subsets were
combined in 1:1 combination and ﬁnally results from all the
possible combinations were downloaded into an EndNote
library. Based on our research question, we also manually
searched the references in all known articles to identify studies
that were missed by the initial search. An ethics approval was
obtained from the institutional review board (IRB) for this study.
The selection criteria for the included studies were: recruited
subjects with macular edema or diabetes mellitus either type 1 or
type 2, discussed the cost-effectiveness or cost-utility of teleophthalmology screening, provided data on the sensitivity or
speciﬁcity of Teleretinal screening. Studies with insufﬁcient data,
discussing only the prevalence of diabetes, case reports, and
conference papers were excluded, as studies with no enough
description of its subjects.

3.1. Summary characteristics of the included studies for
diagnostic accuracy
A total of 33 studies were selected for the analysis. All these
studies used Teleretinal screening either alone or in comparison
to other screening modalities like ophthalmoscopy, slit-lamp
examination, or 7-ﬁeld Early Treatment Diabetic Retinopathy
Screening (ETDRS). Both men and women with either type 1 or
type 2 studies were included in the recruited studies, except
Hubbard et al[10] study which included patients with type 1 DM
only. More than 10,000 people from 8 different countries were
screened in all the studies. Almost 80% of the total studies were
conducted in the UK, Canada, and at various states of the United
States. In >50% of the included studies, digital imaging was
carried out with mydriasis except for Hansen et al[11] and
Lawrence[12] study in which both mydriatic and non-mydriatic
images were obtained. Images were transferred through a secure
web browser, telemetrically, or via an online network.[13–16] A
description of the included studies for diagnostic accuracy is
presented in Table 1.

2.2. Study selection
The titles and abstracts of the selected articles were reviewed
independently by 3 authors and the articles which met the
inclusion criteria were reviewed by the fourth author. Full-text
articles that were potentially relevant to the study were also
reviewed by all the 4 authors to conﬁrm the eligibility.
Disagreements were resolved by mutual consensus and after a
detailed group discussion.

4. Discussion
4.1. Diagnostic accuracy
The cumulative diagnostic accuracy of teleophthalmology for
diabetic macular edema (DME) showed a mean sensitivity of
59% with a range as <30% and a maximum value of 88%.
While speciﬁcity ranged from 82% to 98% with a mean of 93%
and a standard deviation of about 6%. While for clinically
signiﬁcant macular edema (CSME) these values were 38% and
100%, respectively. The mean for CSME was 66%, the standard

2.3. Data abstraction and analysis
Two reviewers extracted data on the study characteristics, costeffectiveness, and sensitivity and speciﬁcity of Teleretinal
screening. Disagreements were resolved by consensus and by a
discussion with a third reviewer. After carefully assessing the
extracted data, pooled sensitivity and speciﬁcity were calculated
2
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Figure 1. PRISMA ﬂow sheet of the selected studies.

The speciﬁcity ranged from 69% to 100% and the mean and the
standard deviation was 94% and 9% respectively. The individual
sensitivities and speciﬁcities of the included studies are tabulated
in supplementary table S1, http://links.lww.com/MD/E387.

deviations for both were 26% and 22%, respectively. The
speciﬁcity ranged from 75% to 100% with a mean of 94% and a
standard deviation of about 8%.
Teleophthalmology was found to be 87% sensitive and 91%
speciﬁc for the absence of retinopathy. For mild non-diabetic
proliferative diabetic retinopathy (NPDR), the total number of
articles was 16, with a minimum value of sensitivity 35% and a
maximum value of 93% with a mean of 74% and the standard
deviation was 0.16481. The mean speciﬁcity ranged from none to
98% with a mean of 50% and the standard deviation was 44%.
The sensitivity of moderate NPDR was reported in 15 articles
having a minimum to maximum range 32% to 100% with a
mean and standard deviation of 71% and 19% respectively.
These values for speciﬁcity ranged from none to 98% with a
mean and standard deviation of only 48% and 47% respectively.
For severe NPDR, the mean sensitivity was 42% with a standard
deviation of 27% and a range from none to 79%. Surprisingly the
speciﬁcity of telemedicine was very high ranging from 94% to
100% and a mean of 94% having only 1% of standard deviation.
As far as individuals with low risk proliferative diabetic
retinopathy (PDR) were concerned, the teleophthalmology was
found to 75% sensitive with respect to the gold standard
ophthalmoscopy with a range from 0% to 100% among different
studies. These values were ironically high for mean speciﬁcity that
was 98% ranging from 94% to 100% among individual studies
having a negligible standard deviation of only 2%. Lastly, for
high-risk PDR, the minimum sensitivity value of 0.00 and a
maximum value of 100% were found among studies while the
mean sensitivity was 76% and the standard deviation was 31%.

4.2. Quality assessment of included studies
The detailed quality assessment and risk of bias assessment of the
included studies are summarized in supplementary table S2,
http://links.lww.com/MD/E388 and shown in Fig. 2 below. The
detailed summary of bias assessment is shown in supplementary
ﬁgure S1, http://links.lww.com/MD/E384. Overall the quality of
the studies included in our meta-analysis was high. The allocation
concealment might have introduced a high risk of selection bias in
the Hansen study.[11] Silva performed 2 similar studies in 2012
and the risk of bias assessment could be done only on one study
while the second study had insufﬁcient information. Selection
criteria were well deﬁned in almost all studies. Chances for
detection bias and attrition bias were low as there not enough
unblinded studies or studies reporting incomplete data respectively. Due to complete reporting of outcomes in all studies, the
reporting bias was minimal in all studies.
4.3. Cost-effectiveness
Cost-effective Teleretinal screening programs have been reported
in many clinical settings, including Canada, India, United States,
Norway, and the United Kingdom.[42–60] A total of 28 studies
were identiﬁed assessing the cost-effectiveness of teleophthalmol3
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Table 1
Characteristics of the included studies for the diagnostic accuracy.

Author

Sample size
(patients/
no of eyes)

Mean age/
range, y

Mean duration
of diabetes, y

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Massin et al, 2005, France [17]
Hansen et al, 2004 [11]
Schiffman et al, 2005 [18]
Gangaputra et al, 2011 [19]
Hubbard et al, 2011 [10]
Kernt et al, 2011 [13]
Maker et al, 2012 [20]
Silva et al, 2012 [21]
Kernt et al, 2012 [14]
Tennant et al, 2000, Canada [22]
Gomez-Ulla et al, 2002, Spain [23]
Harding et al, 1995, UK [24]
Li et al, 2010, US [25]
Silva et al, 2012, US [26]
Cavallerano et al, 2012, US [27]
Torok et al, 2015, Hungary [28]
Ting et al, 2012, Aus [29]
Usher et al, 2004, UK [30]
Bursell et al, 2001, US [31]
Russo, et al, 2015, Italy [32]
Pirbhai et al, 2005, UK [33]
Peter et al, 2006, Aus [34]
Rudnisky et al, 2007, Canada [15]

74/147
83/165
111/222
96/157
319/628
34/66
106/211
3864/7728
141/212
121/241
70/126
395/NA
85/152
126/67
158 /316
52/104
136/272
1273/NA
54/108
120/240
118/223
N/A/NA
102/204

52/25–74
47/25–70
57/18–99
62/37–86
48/NA
62/NA
49/19–78
53/NA
64/25–78
57/9.0–83
N/A/NA
60.2/NA
59/33–83
49/24–83
56/22–86
65.2/NA
53.9/NA
N/A/NA
48/20–75
58.8/NA
79.2/NA
N/A/NA
57/18–99

8/0–23
22/1–53
19/1–49
19/NA
27.2/NA
14.3/NA
23.7/NA
12–13/NA
12/3–39
8.5/NA
NA
NA
NA
21.1/(1–51)
7.0/(0.1–42)
16.4/NA
13.9 /NA
N/A
17.7/3–42
11.6/6–9.7
N/A
N/A
1 m–35 yr

24
25
26
27
28
29
30
31
32
33

Cook et al, 2014, UK [35]
Lin et al, 2002, US [16]
Rajalakshmi et al, 2015, India [36]
Boucher et al, 2003,Canada [37]
Andonegui et al, 2010, Spain [38]
Lawrence, 2004, US [12]
Alessandro [39]
Rodríguez [40]
Pritam [41]
Sasso FC [72]

N/A/NA
197/NA
301/602
98/196
1223
N/A
1281
394
564/1128
1907/3814

N/A/NA
NA/21–80
53/43–63
59/26–92
N/A
67.5
65.69 ± 12.64 years
N/A
53 (20–85)
66/57–72

N/A
N/A
12.5 ± 7.3
N/A
N/A
12.4/0–58
1
5
5
8

SNo.

No of ﬁelds, degree,
scope (stereo/mono),
mydriatic use (yes/no)

Image
resolution
(pixels)

5, 45, non-stereoscopic, color, No
5, 45, non-stereoscopic, color, both
15, 55–60, non-stereoscopic, color, no
4–7, 30–60, stereoscopic, color, yes
7, 30, stereoscopic, color, yes
1200, non-stereoscopic, color, yes
7, 30, stereoscopic, color, yes
1100 and 200, stereoscopic, color, no
1180–200, non-stereoscopic, color, no
7, 30, stereoscopic, yes
N/A, 35–45, N/A, no
3, 45, non-stereoscopic, yes
9, 45, monoscopic, color, yes
3 ﬁeld 45°, 2 ﬁeld 30°, stereoscopic, no
NA, 35, stereoscopic, no
7, N/A, N/A, No
3, 35, non-stereoscopic, yes
NA, 45, N/A, N/A, yes
3, 45°, stereoscopic, no
N/A, 20, NA, N/A, yes
N/A, N/A, N/A, yes
Four different ﬁelds, 60/45/30, N/A, yes
7, 30, stereoscopic (ﬁeld1, 3)
non-stereoscopic (ﬁeld3, 7), color, yes
N/A, N/A, N/A, N/A
1, 45°, stereoscopic, no
4, 45, N/A, N/A, yes
2, 45, non stereoscopic, color,no
N/A
N/A,45, non-stereoscopic, color, both
3, 30,N/A, yes
N/A
7, N/A, stereoscopic, color, yes
N/A

1490  960
1450  1026
N/A
N/A
N/A
N/A
1280  1024
1000  1000
3900  3072
2008  3040
N/A
NA
2400/3000  2000
1200  1600
N/A
N/A
N/A
570  570
640  480.
N/A
1024  1024
N/A
3040  2008

Figure 2. Quality assessment of the included studies shows inclusion of well conducted studies.
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N/A
640  480
N/A
1024  768
N/A
640  480
N/A
N/A
N/A
N/A
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Table 2
Cost effectiveness of teleretinal screening and characteristics of the included studies.
SNo.

Author, year,
country

Population
characteristics
[42]

1

Bjorvig et al, 2002, Norway

2

Maberley et al, 2003, Canada

3

Aoki et al, 2004, US

4

Whited et al, 2005, US

5

Li et al, 2012, US[46]

6

Rachapelle et al, 2013, India

7

Kirkizlar et al, 2013, US[48]

8

Phan et al, 2014, US

9

Brady et al, 2014, US

10
11

Maamari et al 2013 [51]
Taylor et al 1999 [52]

[43]

[44]

[45]

[49]

[50]

[47]

Screening modalities

250,42 diabetic patients Conventional evaluation by
ophthalmologist vs digital
images transmitted via email

Screening outcomes

Economic outcomes

Cost comparisons depending
on volume of screening

At higher workloads, telemedicine led
to lower costs; at 200 patients
per year, telemedicine cost $164
per patient and conventional
examinations cost $243.5 per
patient
The camera program was more costeffective, and had the best costper- QALY ratio, at $15,000; the
camera program would cost
<$5000 per year of vision saved
if 65% or more of the population
was screened
Average CE was $882 per QALY for
TO and $947 for non-TO; in the
TO strategy, 12.4% of patients
reached blindness versus 20.5%
in non-TO; ARR for blindness:
8.1%, NNS by TO to prevent a
blindness case: 12.4%
Number of additional cases and
savings with JVN: IHS: 148 cases
and $525 690; VA: 96 PDR
cases and $2 966 111; DoD:
165 and $129,046; JVN provides
better outcomes at lower costs
than clinic-based ophthalmoscopy
in most scenarios
Telemedicine-based DR screening
cost less than conventional
examinations ($49.95 vs $77.80)
Rural TO was cost- effective ($1320
per QALY) compared with no
screening; screening intervals of up
to every 2 years also were costeffective, but annual screening was
not ($3183 per QALY)
TO is CE in most conditions;
telemedicine screening is not CE
in patients aged older than 80
years or in populations with
>3500 patients
Teleretinal screening was associated
with cost reduction to health plan
payers (average cost reduction per
screen of $24.38) and a decrease
in eye clinic physician workload
but failed to match the investment
cost (53% gained back by study
end)
TO screening for PDR resulted in
savings of $36 per patient (base
case), and a median of $48 in the
simulation model
Ocular CellScope $883.22
For this reason, although multiple
photography is a good idea, it is
costly with 35 mm photos
approximately £0.30 each and
Polaroids £1 each; costs which
are increasing.

650

Visits every 6 months by retina
specialists vs photographic
screening with a digital
camera

Costs per sight-year saved
and costs per QALY

10,000

Non Mydriatic retinal camera TO
vs conventional evaluation by
eye care provider

QALYs gained and costs
generated

Large cohort from IHS,
VA, and DoD data

Clinic based ophthalmoscopy
with pupil dilation vs JVN
digital TO system (JVN)

Number of true positive
cases of proliferative DR
detected

611 diabetic patients

Non-Mydriatic fundus camera vs Prevalence of DR/cost
conventional retinal
comparison
examination
Mobile van, optometrist takes 4 QALY gained from TO vs no
dilated stereoscopic 45° ﬁelds
screening, CU at different
digital retinal photographs with
intervals
non mydriatic camera

1000

900, T1D and T2D

TO vs regular ofﬁce visits and
evaluation by ophthalmologist

DR, ME, blindness, and
associated QALYs

1793 diabetic patients

Topcon digital retinal cameras,
non mydriatic imaging

Cost of teleretinal screening

99 (base case),
100,000 trials (Monte
Carlo simulation)

3-ﬁeld non mydriatic fundus
Estimation of costs of
photography; images were
screening for PDR
transmitted to a remote expert
reader
55°, non mydriatic image
Cost of the camera
45°, mydriatic image vs 7 ﬁeld
Cost of the number of
stereo photography
images

N/A
∗197∗∗534

(continued )
5
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Table 2
(continued).
SNo.

Author, year,
country

Population
characteristics

[53]

Screening modalities

64,905 people screened TO vs no screening program

12

Taylor et al 2000

13

Davis et al

14

Invernizzi et al 2015, Italy

15

Lawrenson et al 1995

16

Rein et al, 2011

17

Leese et al, 1993, UK

18

Bjørvig et al, 2002

19

Müller et al, 2006, AUS

[54]

165; 85

[55]

[56]

[57]

[58]

[59]

[60]

Screening outcomes
Number of true positive
cases of proliferative DR
detected

TO vs no screening program

Usual care, transportation
and equipment costs

1281

3-ﬁeld, 30° images vs slit-lamp
funduscopic examination

Cost of image generation

396

50 degree mydriatic images

Usual care and equipment
costs

N/A

TO vs Annual, Biennial and Selfreferral

Cost comparisons depending
on referral duration

2,984/5,968

TO vs no screening program

Cost per patient screened

20–200

TO vs no screening program

Cost comparisons depending
on volume of screening

1695

TO vs no screening program

Usual care and equipment
costs

Economic outcomes
The average cost of screening was
f13.1 1 per patient and the
average cost of identifying a
person requiring laser therapy was
f1110.
Usual care; staff time and fringe
beneﬁts $12. Transportation $19,
supplies and incentives $1: total
$32 DTC intervention; staff time
and fringe beneﬁts $802.
Transportation $217 telemedicine
equipment $225 teaching aids
$45 supplies and incentives $99
mailing and shipping $25 total
$1413 screening eye exam; staff
time and fringe beneﬁts $20
equipment and supplies $266
total $286
For the remote reading of images,
the cost was calculated at €2.50
per reading. The cost of image
generation plus reading was
therefore €4.45 per patient.
Nurse $3 photographer $5 travel and
accommodation $3 ﬁlm $5
ophthalmologist $3 administration
$2 total $21 camera cost
$22,200 carrying case $1100
frame for station wagon $1350
total 24,650 $ depreciated over 5
years at $5000 per annum
Self-referral resulted in average per
person ophthalmologic-related
costs of US $7,368, telemedicine
increased costs by US $3,343,
biennial evaluation by US $3636,
and annual evaluation by US
$4809
The screening programme in Tayside
cost £10 per patient screened
The total cost of examination by
conventional methods was
NKr8555 at a workload of 20
patients per annum and
NKr288,040 at 200 patients per
annum. In comparison, the total
cost of telemedicine examination
was NKr171,102 and NKr194,169
at the same respective workloads
Total study expenditure, including
costs of personnel (AU$131,300),
transportation (AU$16,400),
consumables (AU$20,900) and
equipment (AU$80,100), was
approximately AU$248,500.
Screening cost per participant was
only about AU$145, compared
with AU$433 in the VIP.
(continued )
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Table 2
(continued).
SNo.

Author, year,
country

Population
characteristics
[61]

4312 eyes

20

Thompson et al 1995, UK

21

Brown-Connolly et al 2014

22

Sculpher et al, 1992, UK

23

James et al, 2000, England (64)

24

Facey et al, 2002, Scotland

25

Tu et al, 2004, England

26

Khan et al, 2013, South Africa

27

Lian et al, 2013, Hong Kong

[68]

2766 diabetic patients

28

Kawasaki et al, 2014, Japan

[69]

50,000 hypothetical
cohort

[62]

[63]

[65]

[66]

TO vs no screening program

5219∗, 6426∗∗

∗Non-mydriatic images vs
∗∗Biometric Screening

3423 diabetic patients

Evaluation of 13 screening
options

1363 diabetic patients

Systematic: 3-ﬁeld, nonstereoscopic photography
using mydriasis; opportunistic:
direct ophthalmoscopy

2000 iterations through
Crystal Ball

Conducted by optometrists,
hospitals and GPs at any
opportunity vs a systematic
health authority program,
primarily by digital camera
(mydriatic and non mydriatic
screening)
Topcon non mydriatic model
(professional medical
photographer) vs slit- lamp
biomicroscopy (optometrists)

769 optometric screen
and 874 digital photography

[67]

Screening modalities

14,541, primary care,
T2D

Screening outcomes

Economic outcomes

Cost comparisons depending
on clinical screening
settings

The cost of diagnosis per true
positive case of sight-threatening
retinopathy ranged from £633 to
£ 1079 for general practitioners,
£497 for a mobile communitybased retinal camera, £1546 for a
hospital based retinal camera,
£1028 for opticians and £1033
for hospital physicians.
Vision screening for adults >65
years old 650,17 vs $1,202,906
Cost of different modalities, Cost savings can result with
expected cost per true
systematic screening during the
positive case detected
same appointment as other
routine health checks, compared
to screening requiring additional
visits
Sight-threatening eye disease The CE was £209 and £289 for
systematic and opportunistic
screening, respectively, and
incremental CE was £32 for each
additional case; systematic
screening remained more costeffective than opportunistic
screening
Cost per QALY for the move The most cost-effective modality:
from one screening
combination of single staffed
program to another
hospital units and mobile vans
using non mydriatic digital
photography

Detection of sightthreatening DR

Mobile non mydriatic digital
Cost per blindness case
camera (photographs taken by
averted
a trained technician with
supervision by an ophthalmic
nurse)
Non Mydriatic fundus camera
Uptake of screening and
(optometrist); subsequently
severity of DR detected
graded by optometrist and
ophthalmologists
Incidental diagnosis, non
Rate of detecting DR,
mydriatic 45° photograph in
preventing blindness, and
high risk people, annual
costs of DR management
fundus examinations;
systematic screening by
ophthalmologists using dilated
fundus examination

CE for optometry = total cost/true
positives = £18,454/22 = £839;
cost per patient screened =
£25,599.30/874 = £29.29; CE for
digital photography = £25,599/
30 = £853; CE was poor in both
models
Non Mydriatic fundus photography is
cost-effective; the cost of DR
screening was $22 per person;
ICER was $1206 per blindness
case averted
Lower screening (OR, 0.59; CI,
0.47–0.74) and a lower detection
rate of DR (OR, 0.73; CI, 0.60–
0.90) in the pay group
DR screening program in Japan is
cost-effective compared to the no
systematic screening; blindness
reduction of ∼16%; incremental
cost of $64.6, and incremental
effectiveness of 0.0054 QALYs
per person screened; ICER was
$11,857 per QALY

AA = African American, ARR = absolute risk reduction, CE = cost effectiveness, CI = conﬁdence interval, CU = cost-utility, DoD = Department of Defense, DR = diabetic retinopathy, GP = general practitioner,
ICER = incremental cost-effectiveness ratio, IHS = Indian Health Service, JVN = Joslin Vision Network, ME = macular edema, Nkr = Norwegian Krone, NNS = number needed to screen, NP = nurse practitioner,
OCT = optical coherence tomography, OR = odds ratio, PA = physician assistant, PDR = proliferative diabetic retinopathy, QALY = quality-adjusted life-year, T1D = type 1 diabetes, T2D = type 2 diabetes, TO =
teleophthalmology, VA = Department of Veterans Affairs.

7

Ullah et al. Medicine (2020) 99:25

Medicine

Teleretinal screening would offer more beneﬁts in developing
and underdeveloped countries. A population-based survey in
Nakuru, Kenya revealed that the prevalence of any type of DR
was 35.9% and of severe non-proliferative DR was 13.9%.[70]
Similarly, within Asia-Paciﬁc India has a 10% prevalence of DR
while Indonesia has a prevalence of 43% for DR. We believe that
such developing countries would beneﬁt more from a teleretinal
screening program.[71,72]

ogy screening of DR and ME in these clinical settings. The cost
analysis was done based on delivery modalities (e.g., telemedicine, clinic camera), screening models like systematic screening
versus opportunistic and screening outcomes such as QualityAdjusted Life-Year (QALY), cost per true positive case detection,
DR severity, screening intervals, population, and referral
duration (Table 2).
Populations screened at a younger age, higher HbA1c, using
insulin, or with high transportation costs derive most of the
beneﬁt from Teleretinal screening.[44,48] Besides, disease burden
and population size determine the cost-effectiveness of a
Teleretinal screening program. Compared with conventional
screening, Teleretinal screening was cost-effective at a high
workload. A saving of 74$ and NKr 28,7186 per patient was
noticed in a population of 200 patients per year.[42,59] At lower
workload of 20 patients, the cost-saving for Teleretinal screening
was only about NKr 8384 with respect to the conventional
screening.[59] However, teleophthalmology (TO) was not
economic in patients >80 years of age and in population
>3500 patients, similarly multiple photographies with 35 mm
photos cost approximately £0.30 extra for each image.[48,52]
Furthermore, in many studies, non-mydriatic screening
approaches perform well and were cost-effective compared with
mydriatic use.[43,65,45,46,67]
Subjects with a high socioeconomic condition or those living in
better areas were screened more often but were less likely to have
DR detected, suggesting the importance of access to screening.[68]
Free screening was associated with a higher compliance rate,
higher chances of DR detection, and a decreased workload on
clinic physicians. Multiple studies discussed the approximate cost
of the usual care like supplies and incentives, transportation
charges, staff time, and fringe beneﬁts (19$–32$).[54,56,60] The
per-patient cost of screening was estimated to be 24$ to 36
$.[49,50] If telemedicine equipment and teaching aids were added
the approximate screening cost per participant was about AUS
$145 per visit and about 5000 US $ per annum.[54,56,60] The
systematic screening model was more cost-effective than the
opportunistic screening model in many studies. James et al[64]
showed that the cost was £209 and £289 for systematic and
opportunistic screening, respectively.
Screening interval is also an important factor in determining
the cost-effectiveness of Teleretinal screening in asymptomatic
patients screening every 2 years can save 900 to 1863 US $ than
annual screening.[47,57] Whited et al[45] compared clinic-based
ophthalmoscopy to teleretinal screening at Joslin Vision Network
(JVN) to determine the true positive case detection cost. In Indian
Health Service (IHS) 148 cases saved $525,690, in the
Department of Veterans Affairs (VA) 96 PDR cases saved
$2,966,111 while in the Department of Defense (DoD) 165 cases
saved $129,046, concluding that JVN provides better outcomes
at lower costs than clinic-based ophthalmoscopy in most
scenarios. Tu et al[66] in his study showed that true positive
detection cost of DR on digital photography by TO was
signiﬁcantly lower (£839) than slit-lamp detection cost of DR
(£853) and cost per patient screened was as little as £29.29 per
patient.

6. Conclusion
Teleophthalmology is very sensitive and speciﬁc for the absence
of retinopathy but for the diseased retina, these values have
widespread variations. It is highly speciﬁc for DME, CSME, PDR,
and severe NPDR but non-speciﬁc for mild or moderate NPDR.
The sensitivity of all kind of retinopathies was not impressive.
However, the relatively small cost of Teleretinal screening makes
for an attractive platform for both image acquisition, storage,
interpretation, and transmission. In contrast to clinical examination and conventional screening, Teleretinal screening reduces the
burden in the eye clinic and improves access in remote
environments. Moreover, screening a small number of individuals is not economically sound, and a larger population screening
with the omission of pupillary mydriasis can be more costeffective. Telescreening also increases screening compliance and
prevent blindness in a high number of a population if the services
are offered free of cost.
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